@lunchpoint27
Active 2 years, 9 months ago
Clinical benefits from Two years, including no proof illness activity (NEDA), regarding sufferers receiving peginterferon beta-1a 125 micrograms each Two weeks (Q2W) as well as Georgia Something like 20 mg/ml after every day (QD) had been in comparison through tendency rating matching examination using individual patient data coming from ADVANCE […] View
Hatcher Koenig’s Docs
| Has attachment | Title | Author | Created | Last Edited | Tags |
|---|---|---|---|---|---|
|
There are no docs for this view. |
